DDInter1007 DDInter1376
Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ketamine {u} (Compound) binds {v} (Gene) CYP3A4
Ketamine {u} (Compound) is included by {v} (Pharmacologic Class) General Anesthesia
Ketamine {u} (Compound) causes {v} (Side Effect) Shock
Ketamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Ketamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenoxylate
Ketamine (Compound) binds CYP3A4 (Gene)
Ketamine (Compound) is included by General Anesthesia (Pharmacologic Class)
Ketamine (Compound) causes Shock (Side Effect)
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate